09:46 AM EDT, 09/28/2022 (MT Newswires) -- MaxCyte (MXCT.L) on Wednesday signed a strategic platform license with Vertex Pharmaceuticals to allow the use of its Flow Electroporation technology and ExPERT platform.
The licenses will be used in Vertex's development of CRISPR/Cas9-based gene-edited therapy. MaxCyte will receive platform licensing fees and program-related revenue.
London shares of the non-viral cell engineering company, which is also listed on Nasdaq, were up 7% in mid-afternoon trade.
Price (GBP): £560.00, Change: £+36.00, Percent Change: +6.87%